Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2

  • Sci Immunol. 2019 Dec 13;4(42):eaav7501. doi: 10.1126/sciimmunol.aav7501.
Christopher J A Duncan  1  2 ,  Benjamin J Thompson  3 ,  Rui Chen  3 ,  Gillian I Rice  4 ,  Florian Gothe  3  5 ,  Dan F Young  6 ,  Simon C Lovell  4 ,  Victoria G Shuttleworth  7 ,  Vicky Brocklebank  7 ,  Bronte Corner  7 ,  Andrew J Skelton  3 ,  Vincent Bondet  8 ,  Jonathan Coxhead  9 ,  Darragh Duffy  8 ,  Cecile Fourrage  10 ,  John H Livingston  11 ,  Julija Pavaine  12  13 ,  Edmund Cheesman  14 ,  Stephania Bitetti  14 ,  Angela Grainger  3 ,  Meghan Acres  3 ,  Barbara A Innes  3 ,  Aneta Mikulasova  3 ,  Ruyue Sun  7 ,  Rafiqul Hussain  8 ,  Ronnie Wright  4  15 ,  Robert Wynn  16 ,  Mohammed Zarhrate  17 ,  Leo A H Zeef  18 ,  Katrina Wood  19 ,  Stephen M Hughes  20 ,  Claire L Harris  7 ,  Karin R Engelhardt  3 ,  Yanick J Crow  21  22  23 ,  Richard E Randall  6 ,  David Kavanagh  7  24 ,  Sophie Hambleton  1  25 ,  Tracy A Briggs  26  15
Affiliations
  • 1. Primary Immunodeficiency Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK. [email protected] [email protected] [email protected].
  • 2. Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • 3. Primary Immunodeficiency Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • 4. Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Manchester, UK.
  • 5. Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany.
  • 6. School of Biology, University of St. Andrews, St. Andrews, UK.
  • 7. Complement Therapeutics Research Group, Immunity and Inflammation Theme, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • 8. Immunobiology of Dendritic Cells, Institut Pasteur, Paris, France.
  • 9. Genomics Core Facility, Biosciences Institute, Newcastle University, UK.
  • 10. Plateforme Bioinformatique, Institut Imagine, Paris, France.
  • 11. Department of Paediatric Neurology, Leeds General Infirmary, Leeds, UK.
  • 12. Academic Unit of Paediatric Radiology, Royal Manchester Children's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
  • 13. Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • 14. Department of Paediatric Histopathology, Central Manchester University Foundation NHS Trust, Manchester, UK.
  • 15. Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
  • 16. Department of Paediatric Blood and Marrow Transplant, Royal Manchester Children's Hospital, Oxford Rd., Manchester, UK.
  • 17. Genomics Core Facility, Institut Imagine, Paris, France.
  • 18. Bioinformatics Core Facility, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • 19. Department of Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • 20. Immunology Department, Royal Manchester Children's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
  • 21. MRC Institute of Genetics and Molecular Medicine, Centre for Genomic and Experimental Medicine, The University of Edinburgh, Edinburgh, UK.
  • 22. Laboratory of Neurogenetics and Neuroinflammation, Institut Imagine, Paris, France.
  • 23. Paris Descartes University, Sorbonne-Paris-Cité, Paris, France.
  • 24. National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne Hosptials NHS Foundation Trust, Newcastle upon Tyne, UK.
  • 25. Children's Immunology Service, Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • 26. Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Manchester, UK. [email protected] [email protected] [email protected].
Abstract

Excessive type I interferon (IFNα/β) activity is implicated in a spectrum of human disease, yet its direct role remains to be conclusively proven. We investigated two siblings with severe early-onset autoinflammatory disease and an elevated IFN signature. Whole-exome Sequencing revealed a shared homozygous missense Arg148Trp variant in STAT2, a transcription factor that functions exclusively downstream of innate IFNs. Cells bearing STAT2R148W in homozygosity (but not heterozygosity) were hypersensitive to IFNα/β, which manifest as prolonged Janus kinase-signal transducers and activators of transcription (STAT) signaling and transcriptional activation. We show that this gain of IFN activity results from the failure of mutant STAT2R148W to interact with Ubiquitin-Specific Protease 18, a key STAT2-dependent negative regulator of IFNα/β signaling. These observations reveal an essential in vivo function of STAT2 in the regulation of human IFNα/β signaling, providing concrete evidence of the serious pathological consequences of unrestrained IFNα/β activity and supporting efforts to target this pathway therapeutically in IFN-associated disease.